Search clinical trials for: ribociclib

Total 151 results

AstraZeneca

Not yet recruiting

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01)

Advanced Breast Cancer

Canada
American Society of Clinical Oncology
Patient-Centered Outcomes Research Institute

Not yet recruiting

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Metastatic Breast Cancer
The First Affiliated Hospital with Nanjing Medical...
Zhejiang Cancer Hospital

Recruiting

Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Advanced Breast Cancer

China
Dosentrx Ltd.

Not yet recruiting

Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform

Any Solid Oral Medication

United States
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

Korea, Republic of, United Kingdom, Australia, United States, Spain
Novartis Pharmaceuticals

Recruiting

A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia (ValerEE)

HR+HER2- Advanced Breast Cancer

Russian Federation
Novartis Pharmaceuticals

Recruiting

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

Breast Cancer

Jordan
Hoffmann-La Roche

Recruiting

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Belgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Portugal, Spain, Taiwan, Costa Rica, New Zealand, Poland, Chile, Colombia, Guatemala, Israel, Hungary, India, Thailand
Northwestern University
National Cancer Institute (NCI)

Not yet recruiting

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Estrogen-receptor-positive Breast Cancer | HER2/Neu-Negative Breast Cancer | Advanced Breast Cancerv

United States
University of Michigan Rogel Cancer Center

Recruiting

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer

Breast Cancer

United States
Karolinska University Hospital

Recruiting

Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (ARIADNE)

Breast Cancer

Sweden
Novartis Pharmaceuticals

Recruiting

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Breast Cancer

France, Spain, Portugal
Nationwide Children's Hospital
Novartis

Not yet recruiting

Study of Ribociclib and Everolimus in HGG and DIPG

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | WHO Grade IV Glioma

United States, Australia, United Kingdom, Canada, Germany, Netherlands
University of Miami

Recruiting

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Breast Cancer | Metastatic Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer

United States
Korea University Guro Hospital

Recruiting

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Metastatic Breast Cancer

Korea, Republic of
National Taiwan University Hospital

Recruiting

A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC (ORACLE-RIPA)

Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Therapy

Taiwan
Novartis Pharmaceuticals

Recruiting

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France (RosaLEE)

Breast Cancer

France
Centre Antoine Lacassagne

Recruiting

Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS) (CALHYS)

HER2 Negative Breast Cancer Not Immediately Operated

France
UNICANCER
Novartis; Breast Cancer Research Foundation

Recruiting

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib (SAFIR 03)

Breast Cancer Stage IV

France
CMC Ambroise Paré

Recruiting

A Deep Learning Method to Evaluate QT on Ribociclib (QT-RIBRATING)

Breast Cancer | Ribociclib

France
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

Breast Cancer

United States, Canada, Spain, Italy
Stemline Therapeutics, Inc.

Recruiting

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)

Breast Cancer | Metastatic Breast Cancer

United States
Olema Pharmaceuticals, Inc.
Novartis

Recruiting

Phase 1b Combo w/ Ribociclib and Alpelisib

Advanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast Cancer

United States, Australia
Oana Danciu
Novartis Pharmaceuticals

Recruiting

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR)

HER2-negative Breast Cancer | Locoregional Recurrence | Hormone Receptor-positive Breast Cancer

United States
Institut fuer Frauengesundheit
Novartis Pharmaceuticals; AGO Breast Study Group e.V.

Recruiting

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients (CAPTOR-BC)

Breast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer

Germany
Novartis Pharmaceuticals
Innovative Therapies For Children with Cancer Consortium

Recruiting

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Neuroblastoma

Germany, Italy, Singapore, Spain, United States, Australia, France
Novartis Pharmaceuticals

Recruiting

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-03)

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Colorectal Cancer | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal | Non-Small Cell Lung Carcinoma | KRAS G12C Mutant Solid Tumors

Korea, Republic of, Spain, Belgium, United States, France, Germany, Italy, Singapore
Jonsson Comprehensive Cancer Center
Novartis; Seagen Inc.

Recruiting

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
SOLTI Breast Cancer Research Group
Novartis; UNICANCER

Recruiting

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (RIBOLARIS)

Breast Cancer Stage II

Spain, France, Portugal
Blueprint Medicines Corporation

Recruiting

(VELA) Study of BLU-222 in Advanced Solid Tumors

Gastric Cancer | Ovarian Cancer | Carcinosarcoma | Advanced Solid Tumors | Endometrial Cancer | Esophageal Adenocarcinoma | HER2-negative Breast Cancer | CCNE1 Amplification | HR+ Breast Cancer

United States, Italy, United Kingdom
Relay Therapeutics, Inc.

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Unresectable Solid Tumor | PIK3CA Mutation

United States, Spain, France, Italy
SOLTI Breast Cancer Research Group
Novartis; Alliance Foundation Trials, LLC.

Recruiting

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype (HARMONIA)

Metastatic Breast Cancer

United States, Spain, Portugal
Pfizer

Recruiting

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Solid Tumors

United States, Spain, Canada, Italy, Australia, Hungary, Netherlands, United Kingdom, Germany, Brazil, Korea, Republic of, Portugal, France, Japan, Israel, Slovakia, Czechia
University Hospital, Akershus
Vestre Viken Hospital Trust; Novartis

Recruiting

Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole (NEOLETRIB)

Breast Cancer | Locally Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Luminal A Breast Cancer | Luminal B Breast Cancer

Norway
Novartis Pharmaceuticals

Recruiting

Roll-over Study to Allow Continued Access to Ribociclib

Metastatic Breast Cancer

United States, Lebanon, Hong Kong, Turkey, Vietnam, Brazil, Italy, Korea, Republic of, Poland, Taiwan, Singapore, Japan, South Africa, Spain, Costa Rica, Greece, Portugal, Argentina, Mexico
Namik Kemal University

Not yet recruiting

Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?

Can the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors

Turkey
AstraZeneca

Recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

United States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
Novartis Pharmaceuticals

Recruiting

A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia (PROSPERITY)

Breast Cancer

Russian Federation
Royal Marsden NHS Foundation Trust
Pfizer; Hoffmann-La Roche

Recruiting

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression (FAIM)

Advanced Breast Cancer | Metastatic Breast Cancer | ER+ Breast Cancer

United Kingdom
AstraZeneca

Recruiting

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (CAPItello-292)

Locally Advanced (Inoperable) or Metastatic Breast Cancer

United States, Spain, Denmark, Korea, Republic of, Germany, Belgium, Vietnam, United Kingdom, France, Japan, Brazil, Canada, China, Malaysia, Taiwan, Thailand, Australia, Turkey, Argentina, India, Poland, Sweden, Italy
Blokhin's Russian Cancer Research Center

Recruiting

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Breast Cancer Stage IV

Russian Federation
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

United States, Korea, Republic of, Spain, Australia, Israel
Fondazione Sandro Pitigliani
Clinical Research Technology S.r.l.

Recruiting

To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer (TIRESIAS)

Metastatic Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer

Italy
University of Utah
Novartis; Acrotech Biopharma

Recruiting

Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE)

Metastatic Breast Cancer | Recurrent Ovarian Carcinoma

United States
Centre Leon Berard

Recruiting

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)

Malignant Solid Tumor

France
West German Study Group
Novartis; Genomic Health®, Inc.

Recruiting

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC (ADAPTcycle)

Breast Cancer Female

Germany
Yonsei University

Recruiting

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Metastatic Breast Cancer | HER2-positive Breast Cancer | Postmenopausal

Korea, Republic of
Hoffmann-La Roche
Gilead Sciences; Seagen Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (Morpheus-panBC)

Breast Cancer

Korea, Republic of, Spain, United States, Israel, United Kingdom, France, Australia, Germany
Massachusetts General Hospital
Novartis

Recruiting

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer (LEADER)

Breast Cancer

United States
Kari Wisinski
Novartis; University of Wisconsin, Madison; Big Ten Cancer Research Consortium

Recruiting

Ribociclib and Bicalutamide in AR+ TNBC

Triple Negative Breast Cancer

United States

Search clinical trials for: ribociclib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations